Sorrento Announces Subsidiary Company – ADNAB, Inc. – to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic
The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical…